Sign in
Taking peopleNo phase

Transcutaneous Auricular Vagus Nerve Stimulation as Adjuvant Treatment for Sepsis Patients

Key facts

Who runs it
Third Military Medical University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
60 people, planned
Started
27 Feb 2025
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • taVNS
  • sham-taVNS
Record updated
4 July 2025

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • Age 18-80
  • Sepsis was diagnosed per the Sepsis-3 criteria (SCCM/ESICM 2016) as infection with SOFA score ≥ 2
  • ICU admission within 7 days after sepsis onset
  • Informed consent was obtained from patients/guardians

Who cannot take part

  • taVNS contraindications: existing pacemakers, cochlear implants, or other active implantable electronic medical devices
  • severe underlying pulmonary diseases including interstitial lung disease, -
  • diffuse alveolar hemorrhage, severe asthma, or lung cancer
  • dermatologic or infectious disorders affecting the auricular region
  • inability to remain motionless during treatment (e.g., due to epilepsy or Parkinson's disease)
  • severe ARDS defined by PaO₂/FiO₂ ≤100 mmHg with PEEP ≥5 cm H₂O
  • HR>120 per minute
  • epinephrine or norepinephrine >1ug/kg/min
  • pregnancy or lactation
  • participation in other clinical trials

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Sepsis

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goals of this randomized clinical trial are to investigate the effects of transcutaneous auricular vagus nerve stimulation (taVNS) combined with standard intensive care on systemic organ function in septic patients, and exploring its potential mechanisms for improving overall outcomes in sepsis.The main question it aims to answer is whether taVNS can reduce the severity of sepsis patients by ameliorating systemic inflammation.Participants will receive standard intensive care treatment and be randomized to receive the taVNS or sham taVNS as adjuvant treatment twice a day for 7 consecutive days. Several evaluations will be done before and after the intervention.

The 2 groups in the trial

  • taVNS groupTreatment being tested

    transcutaneous auricular vagus nerve stimulation twice a day for 7 consecutive days.

    Treatment: taVNS

  • sham-taVNS groupSham treatment, for comparison

    sham transcutaneous auricular vagus nerve stimulation twice a day for 7 consecutive days.

    Treatment: sham-taVNS

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Exploratory Study on Transcutaneous Auricular Vagus Nerve Stimulation as Adjuvant Treatment for Sepsis Patients
Criteria questions
Built from NCT07051694, who can take part
Record updated
4 July 2025